Verastem Inc
VSTM8.060USD
+0.190+2.41%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
538.00MMarket Cap
LossP/E TTM
More Details of Verastem Inc Company
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Verastem Inc Info
Ticker SymbolVSTM
Company nameVerastem Inc
IPO dateNov 08, 2011
CEOPaterson (Daniel W)
Number of employees78
Security typeOrdinary Share
Fiscal year-endNov 08
Address117 Kendrick Street
CityNEEDHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02494
Phone17812924200
Websitehttps://www.verastem.com/
Ticker SymbolVSTM
IPO dateNov 08, 2011
CEOPaterson (Daniel W)
Company Executives of Verastem Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel W. (Dan) Paterson
Mr. Daniel W. (Dan) Paterson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
149.95K
-8.54%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Director
Director
95.38K
-0.61%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Director
Director
38.95K
-0.72%
Mr. Daniel (Dan) Calkins
Mr. Daniel (Dan) Calkins
Chief Financial Officer
Chief Financial Officer
30.86K
-0.26%
Mr. Anil Kapur
Mr. Anil Kapur
Independent Director
Independent Director
15.97K
+109.10%
Ms. Michelle Robertson
Ms. Michelle Robertson
Independent Director
Independent Director
15.97K
+109.10%
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Lead Independent Director d
Lead Independent Director d
7.97K
-51.75%
Mr. Matthew E. (Matt) Ros
Mr. Matthew E. (Matt) Ros
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Julissa Viana
Ms. Julissa Viana
Investor Relations
Investor Relations
--
--
Dr. Paul Bunn, M.D.
Dr. Paul Bunn, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel W. (Dan) Paterson
Mr. Daniel W. (Dan) Paterson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
149.95K
-8.54%
Mr. Brian M. Stuglik
Mr. Brian M. Stuglik
Director
Director
95.38K
-0.61%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Director
Director
38.95K
-0.72%
Mr. Daniel (Dan) Calkins
Mr. Daniel (Dan) Calkins
Chief Financial Officer
Chief Financial Officer
30.86K
-0.26%
Mr. Anil Kapur
Mr. Anil Kapur
Independent Director
Independent Director
15.97K
+109.10%
Ms. Michelle Robertson
Ms. Michelle Robertson
Independent Director
Independent Director
15.97K
+109.10%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 24
Updated: Mon, Nov 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
7.03%
Balyasny Asset Management LP
5.37%
Logos Global Management LP
5.25%
Point72 Asset Management, L.P.
5.03%
Deep Track Capital LP
4.99%
Other
72.33%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
7.03%
Balyasny Asset Management LP
5.37%
Logos Global Management LP
5.25%
Point72 Asset Management, L.P.
5.03%
Deep Track Capital LP
4.99%
Other
72.33%
Shareholder Types
Shareholders
Proportion
Hedge Fund
30.97%
Investment Advisor/Hedge Fund
20.98%
Investment Advisor
14.14%
Venture Capital
8.74%
Private Equity
5.21%
Research Firm
3.06%
Individual Investor
0.59%
Bank and Trust
0.07%
Insurance Company
0.02%
Other
16.22%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
227
53.29M
80.22%
-2.84M
2025Q2
222
45.13M
81.89%
-1.03M
2025Q1
244
43.61M
79.40%
-4.23M
2024Q4
235
34.35M
77.18%
-2.65M
2024Q3
242
27.08M
67.33%
+202.45K
2024Q2
244
15.08M
59.39%
-6.47M
2024Q1
256
17.10M
67.53%
-4.40M
2023Q4
273
17.07M
67.53%
-4.59M
2023Q3
291
17.14M
67.93%
-3.81M
2023Q2
301
16.47M
65.35%
+4.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
4.25M
6.91%
+6.14K
+0.14%
Jun 30, 2025
Balyasny Asset Management LP
4.21M
6.83%
-582.01K
-12.16%
Jun 30, 2025
Logos Global Management LP
3.42M
5.57%
+2.42M
+242.50%
Jul 21, 2025
Point72 Asset Management, L.P.
3.34M
5.42%
+3.34M
--
Jul 25, 2025
The Vanguard Group, Inc.
3.42M
5.56%
+993.51K
+40.88%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.49M
4.04%
+161.01K
+6.92%
Jun 30, 2025
Foresite Capital Management, LLC
1.28M
2.07%
+1.28M
--
Jun 30, 2025
Stonepine Capital Management, LLC
1.50M
2.44%
+139.61K
+10.26%
Jul 22, 2025
Vivo Capital, LLC
1.54M
2.5%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Dorsey Wright Healthcare Momentum ETF
0.63%
State Street SPDR S&P Biotech ETF
0.27%
Vanguard US Momentum Factor ETF
0.15%
Fidelity Enhanced Small Cap ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
iShares Micro-Cap ETF
0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Pacer WealthShield ETF
0.03%
ProShares Hedge Replication ETF
0.02%
Global X Russell 2000 ETF
0.02%
View more
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.63%
State Street SPDR S&P Biotech ETF
Proportion0.27%
Vanguard US Momentum Factor ETF
Proportion0.15%
Fidelity Enhanced Small Cap ETF
Proportion0.14%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.13%
iShares Micro-Cap ETF
Proportion0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
Pacer WealthShield ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
Date
Type
Ratio
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
May 31, 2023
Merger
12→1
FAQs
Who are the top five shareholders of Verastem Inc?
The top five shareholders of Verastem Inc are:
RTW Investments L.P. holds 4.25M shares, accounting for 6.91% of the total shares.
Balyasny Asset Management LP holds 4.21M shares, accounting for 6.83% of the total shares.
Logos Global Management LP holds 3.42M shares, accounting for 5.57% of the total shares.
Point72 Asset Management, L.P. holds 3.34M shares, accounting for 5.42% of the total shares.
The Vanguard Group, Inc. holds 3.42M shares, accounting for 5.56% of the total shares.
RTW Investments L.P. holds 4.25M shares, accounting for 6.91% of the total shares.
Balyasny Asset Management LP holds 4.21M shares, accounting for 6.83% of the total shares.
Logos Global Management LP holds 3.42M shares, accounting for 5.57% of the total shares.
Point72 Asset Management, L.P. holds 3.34M shares, accounting for 5.42% of the total shares.
The Vanguard Group, Inc. holds 3.42M shares, accounting for 5.56% of the total shares.
What are the top three shareholder types of Verastem Inc?
The top three shareholder types of Verastem Inc are:
RTW Investments L.P.
Balyasny Asset Management LP
Logos Global Management LP
RTW Investments L.P.
Balyasny Asset Management LP
Logos Global Management LP
How many institutions hold shares of Verastem Inc (VSTM)?
As of 2025Q3, 227 institutions hold shares of Verastem Inc, with a combined market value of approximately 53.29M, accounting for 80.22% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.67%.
What is the biggest source of revenue for Verastem Inc?
In --, the -- business generated the highest revenue for Verastem Inc, amounting to -- and accounting for --% of total revenue.
